What “exact patent end date” can mean for apixaban
“Patent end date” can refer to different legal events, depending on the country and the specific right being discussed: the end of the primary (active) patent term, the end of any patent term adjustments, or the end of data/exclusivity periods that can still block generic or biosimilar competition even after a patent expires. Without a specific jurisdiction and patent number, there is no single “exact date” that’s universally correct.
What I can and can’t provide from the information available here
I don’t have any provided details in this chat that identify:
- the jurisdiction (e.g., US, EU, UK, Canada, India),
- the specific apixaban patent(s) (or patent numbers),
- whether you mean the last listed patent expiration date or the earliest,
- or whether you mean market exclusivity rather than patent expiry.
Because of that, I can’t state the exact date apixaban’s patent ends.
The fastest way to get the exact date you want
If you tell me the jurisdiction (for example, “US” or “EU”) and whether you mean:
- earliest patent expiry, or
- last patent expiry (the one that ends generic entry risk),
I can narrow the answer to the right event type.
Quick clarifying questions
1) Which country/region do you mean for the patent end date?
2) Do you want the last apixaban patent to expire (usually what matters for generic entry), or the earliest?
If you share one more detail, I can be precise
If you paste the patent number (or a link to the listing you’re using), I can help interpret it and translate it into the exact expiration date tied to that right.